Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases gastric acid production.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally or intravenously twice daily, with subsequent doses adjusted based on acid output. Doses can be increased up to 240 mg per day divided into infusions.
## Pediatric Dosing
* **Erosive esophagitis (12 to 17 years):** 40 mg orally once daily for up to 8 weeks.
* **Erosive esophagitis (5 to 11 years):**
* For patients weighing < 40 kg: 20 mg orally once daily for up to 8 weeks.
* For patients weighing ≥ 40 kg: 40 mg orally once daily for up to 8 weeks.
* **Note:** Data for pantoprazole in children younger than 5 years for erosive esophagitis is limited. Dosing for other indications in pediatrics is not well-established.
## Dose Adjustments
* No dose adjustment is generally recommended for patients with hepatic impairment, though caution is advised.
* No dose adjustment is generally recommended for patients with renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of its formulation.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, flatulence.
* Serious: Potential for increased risk of fractures (hip, wrist, spine) with long-term use, *Clostridioides difficile*-associated diarrhea, hypomagnesemia (especially with prolonged use), vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Absorption may be decreased (e.g., ketoconazole, itraconazole, iron salts, mycophenolate mofetil, dasatinib). Separate administration by at least 12 hours.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider dose reduction or interruption of pantoprazole or monitor methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel (though clinical significance is debated and often mitigated by genetic factors).
## Monitoring
* Monitor for signs and symptoms of *Clostridioides difficile*-associated diarrhea.
* Monitor serum magnesium levels periodically, especially with prolonged use (e.g., > 1 year).
* Monitor for signs of vitamin B12 deficiency with prolonged use.
* Monitor bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* IV formulation is available for patients unable to take oral medication.
* Pantoprazole may be taken with or without food.
* Long-term use of PPIs should be reserved for specific indications due to potential risks. The lowest effective dose should be used for the shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for definitive guidance. Dosing may vary based on individual patient factors and clinical circumstances.
